Zydus Cadila receives EIR for Moraiya manufacturing facility
Mumbai: Pharma Major, Zydus Cadila's formulations manufacturing facility at Moraiya, Ahmedabad has received an Establishment Inspection Report (EIR) from the United States Food & Drug Administration (USFDA) signifying the successful closure of the audit.
The Moraiya manufacturing plant had completed the USFDA audit from February 6th to 15th 2017 with Zero 483 observations.
Post the audit, the plant has received several product approvals,including the final approval to market Mesalamine Delayed- Release Tablets USP, 1.2 g in the US.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd